Regeneron Pharmaceuticals (REGN) is forecasting annual earnings growth of 7.41%, with revenue also projected to rise by 7% ...
Regeneron Pharmaceuticals recently saw its Fair Value price target increased from $722.20 to $735.72. This change comes on ...
Regeneron and ModeX Therapeutics have joined forces in a collaboration worth over one billion dollars to develop ...
3h
Libtayo® (cemiplimab for injection) Now Reimbursed in Québec for Advanced Non-Small Cell Lung Cancer
CNW/ - Company announced today that Libtayo® (cemiplimab for injection) is now reimbursed by Régie de l'assurance maladie du ...
CNW/ - Company announced today that Libtayo® (cemiplimab for injection) is now reimbursed by public drug programs in Ontario, ...
US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) has entered a license and collaboration deal with OPKO Health’s (Nasdaq: ...
ModeX Therapeutics enters research collaboration with Regeneron to develop multispecific antibodies for select therapeutic indications: Weston, Massachusetts Thursday, October 30, ...
Physical function decline is an increasingly recognised concern among individuals with long-term conditions such as Type 2 ...
Anogenital lichen planus (ALP) is a chronic inflammatory condition associated with significant morbidity, persistent symptoms ...
At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.
Fintel reports that on October 29, 2025, Guggenheim maintained coverage of Regeneron Pharmaceuticals (NasdaqGS:REGN) with a ...
Fintel reports that on October 29, 2025, Wells Fargo maintained coverage of Regeneron Pharmaceuticals (NasdaqGS:REGN) with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback